Literature DB >> 28064216

Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.

Christos Perisanidis1.   

Abstract

BACKGROUND: Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain (TKD) are associated with response and resistance to targeted therapy. The EGFR mutation status in patients with advanced oral and oropharyngeal squamous cell carcinoma (OOSCC) was evaluated. A systematic literature review was undertaken to summarize current evidence and estimate the overall prevalence of EGFR TKD mutations in patients with head and neck squamous cell carcinoma (HNSCC).
MATERIALS AND METHODS: Genomic DNA was extracted from formalin-fixed, paraffin-embedded tumor samples of 113 patients with OOSCC. Pyrosequencing was performed to investigate mutations in EGFR exons 18 to 21. Medline databases were searched for relevant studies. Studies reporting mutations in the EGFR TKD in HNSCC were eligible for inclusion in the systematic review.
RESULTS: No mutations in the EGFR TKD were observed in 113 samples of OOSCC. A total of 53 eligible studies were included in the systematic review. In total, from the review, 117 patients harboring a total of 159 EGFR TKD mutations were reported among 4122 patients with HNSCC. The overall prevalence of EGFR TKD mutations in HNSCC was 2.8%.
CONCLUSION: Large-scale studies are warranted to provide further evidence regarding the mutation status of EGFR in patients with HNSCC. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  EGFR kinase domain; Oral and oropharyngeal cancer; mutations; pyrosequencing; review

Mesh:

Substances:

Year:  2017        PMID: 28064216      PMCID: PMC5354143          DOI: 10.21873/invivo.11020

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  77 in total

1.  Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.

Authors:  P Smilek; J Neuwirthova; J Jarkovsky; L Dusek; J Rottenberg; R Kostrica; J Srovnal; M Hajduch; J Drabek; J Klozar
Journal:  Neoplasma       Date:  2012       Impact factor: 2.575

Review 2.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

3.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

4.  Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.

Authors:  Sven Bontognali; Miklos Pless; Martin H Brutsche; Claude Fischer; Christoph Rochlitz; Martin Buess
Journal:  Onkologie       Date:  2013-03-18

5.  Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers.

Authors:  Curtis R Pickering; Jiexin Zhang; David M Neskey; Mei Zhao; Samar A Jasser; Jiping Wang; Alexandra Ward; C Jillian Tsai; Marcus V Ortega Alves; Jane H Zhou; Jennifer Drummond; Adel K El-Naggar; Richard Gibbs; John N Weinstein; David A Wheeler; Jing Wang; Mitchell J Frederick; Jeffrey N Myers
Journal:  Clin Cancer Res       Date:  2014-05-29       Impact factor: 12.531

6.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

Authors:  Denis Soulieres; Neil N Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

7.  EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan.

Authors:  Shiang-Fu Huang; Wen-Yu Chuang; I-How Chen; Chun-Ta Liao; Hung-Ming Wang; Ling-Ling Hsieh
Journal:  Head Neck       Date:  2009-08       Impact factor: 3.147

8.  Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma.

Authors:  Mahmoud A L Sheikh Ali; Mehmet Gunduz; Hitoshi Nagatsuka; Esra Gunduz; Beyhan Cengiz; Kunihiro Fukushima; Levent Bekir Beder; Kadir Demircan; Masae Fujii; Noboru Yamanaka; Kenji Shimizu; Reidar Grenman; Noriyuki Nagai
Journal:  Cancer Sci       Date:  2008-08       Impact factor: 6.716

9.  Novel insight into mutational landscape of head and neck squamous cell carcinoma.

Authors:  Daria A Gaykalova; Elizabeth Mambo; Ashish Choudhary; Jeffery Houghton; Kalyan Buddavarapu; Tiffany Sanford; Will Darden; Alex Adai; Andrew Hadd; Gary Latham; Ludmila V Danilova; Justin Bishop; Ryan J Li; William H Westra; Patrick Hennessey; Wayne M Koch; Michael F Ochs; Joseph A Califano; Wenyue Sun
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

10.  Molecular profiling of head and neck squamous cell carcinoma.

Authors:  Rebecca Feldman; Zoran Gatalica; Joseph Knezetic; Sandeep Reddy; Cherie-Ann Nathan; Nader Javadi; Theodoros Teknos
Journal:  Head Neck       Date:  2015-11-28       Impact factor: 3.147

View more
  11 in total

1.  Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.

Authors:  Shilpa Bhatia; Jaspreet Sharma; Sanjana Bukkapatnam; Ayman Oweida; Shelby Lennon; Andy Phan; Dallin Milner; Nomin Uyanga; Antonio Jimeno; David Raben; Hilary Somerset; Lynn Heasley; Sana D Karam
Journal:  Clin Cancer Res       Date:  2018-05-30       Impact factor: 12.531

Review 2.  Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews.

Authors:  Miguel Ángel González-Moles; Saman Warnakulasuriya; María López-Ansio; Pablo Ramos-García
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

3.  EGFR in head and neck squamous cell carcinoma: exploring possibilities of novel drug combinations.

Authors:  Hina S Rehmani; Natalia Issaeva
Journal:  Ann Transl Med       Date:  2020-07

4.  Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report.

Authors:  Mie Mie Thinn; Chung-Tzu Hsueh; Chung-Tsen Hsueh
Journal:  World J Clin Cases       Date:  2019-03-06       Impact factor: 1.337

5.  A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.

Authors:  Madelyn Espinosa-Cotton; Elana J Fertig; Laura P Stabile; Autumn Gaither-Davis; Julie E Bauman; Sandra Schmitz; Katherine N Gibson-Corley; Yinwen Cheng; Isaac J Jensen; Vladimir P Badovinac; Douglas Laux; Andrean L Simons
Journal:  Biomark Res       Date:  2019-07-16

Review 6.  New Insights into Oral Cancer-Risk Factors and Prevention: A Review of Literature.

Authors:  Soussan Irani
Journal:  Int J Prev Med       Date:  2020-12-30

7.  Study of EGFR mutations in head and neck squamous cell carcinomas.

Authors:  Gurpreet Kaur; Deepika Phogat; Venkatesan Manu
Journal:  Autops Case Rep       Date:  2021-04-15

8.  Uncovering drug repurposing candidates for head and neck cancers: insights from systematic pharmacogenomics data analysis.

Authors:  Annie Wai Yeeng Chai; Aik Choon Tan; Sok Ching Cheong
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

9.  Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.

Authors:  Rintu Thomas; Zhang Weihua
Journal:  Front Oncol       Date:  2019-08-23       Impact factor: 6.244

Review 10.  Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance.

Authors:  Saima Usman; Ahmad Jamal; Muy-Teck Teh; Ahmad Waseem
Journal:  Front Oral Health       Date:  2021-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.